Drug Type Biological products |
Synonyms |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization NaNotics LLCStartup |
Active Organization NaNotics LLCStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Brain Cancer | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Head and Neck Neoplasms | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Liver Cancer | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Lung Cancer | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
MRSA - Methicillin resistant Staphylococcus aureus infection | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Nasopharyngeal Carcinoma | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Prostatic Cancer | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Systemic Lupus Erythematosus | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Uterine Cervical Cancer | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Well Aging | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |